Evidence map›Paper›PMID 41050086›Full record

ReviewOncology research2025

Nanotechnology-Driven Treatment Strategies for Breast Cancer: Recent Advances and Innovations.

Neha Raina, Radha Rani, Mahika Kanojia, Avril Mathias, Keshav Raj Paudel, Ashish Garg, Hardeep Singh Tuli, A T M Mijanur Rahman, Vetriselvan Subramaniyan, Madhu Gupta

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Neha RainaCentre for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai, 602105, India.
Radha RaniDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi, 110017, India.
Mahika KanojiaDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi, 110017, India.
Avril MathiasDepartment of Pharmaceutics, Nitte College of Pharmaceutical Sciences, Bangalore, 560064, India.
Keshav Raj PaudelCentre for Inflammation, Faculty of Science, School of Life Sciences, Centenary Institute and University of Technology Sydney, Sydney, NSW 2050, Australia.
Ashish GargDepartment of Pharmaceutics, Guru Ramdas Khalsa Institute of Science and Technology, Jabalpur, 483001, India.
Hardeep Singh TuliCentre of Excellence in Computational Research and Drug Discovery, Department of Bio-Sciences and Technology, Maharishi Markandeshwar Engineering College, Maharishi Markandeshwar (Deemed to Be University), Mullana, Ambala, India.
A T M Mijanur RahmanBio-nanotechnology and Nanomedicine Lab., Dept. of Applied Nutrition and Food Technology, Islamic University, Kushtia, 7003, Bangladesh.
Vetriselvan SubramaniyanDivision of Pharmacology, Faculty of Medical and Life Sciences, Sunway University, Bandar Sunway, 47500, Malaysia.
Madhu GuptaDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi, 110017, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is among the most prevalent cancers in females globally and has the highest mortality rate. The emergence of pharmacologic resistance in breast cancer is a significant challenge for researchers in the pursuit of effective treatment. Investigations in cancer nanotechnology have been transformed by the advancement of smart polymers, lipids, and inorganic materials. Research is now being conducted in the field of innovative nano-pharmaceutical formulations aimed at enhancing the efficacy and durability of chemotherapy. Nanotechnology-based delivery systems are beneficial for combating breast cancer due to theranostic applications, augmented drug encapsulation, decreased degradation, and minimal adverse effects. This review discusses breast cancer and its stages, various risk factors, and pathogenesis, in addition to diagnosis and treatment. Novel nanocarriers are included with the most recent findings in this area and the potential use of these nanocarriers in cancer therapy that centers on their clinical usage for improved treatment. Patents and promising clinical trial results are also explained in detail, with nanotoxicity, ethical concerns, and regulations. This study underscores the importance of treatment strategies using nanotechnology, highlighting the advancing paradigm of breast cancer care. This article examines the prospects, obstacles, and future trajectories of nanomedicines.

Indexed as

Antineoplastic AgentsBreast NeoplasmsNanomedicineNanotechnologyDrug Delivery SystemsFemaleHumansNanoparticlesAntineoplastic AgentsBreast cancerclinical trialsdiagnosisnanotechnologytherapeutic strategy

Identifiers

PMID41050086
PMCPMC12494100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.